TY - JOUR
T1 - Nano-chemotherapeutics
T2 - Maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers
AU - Ryan, Gemma
AU - Kaminskas, Lisa Michelle
AU - Porter, Christopher John
PY - 2014
Y1 - 2014
N2 - Nano-sized drug delivery systems incorporating chemotherapeutic drugs ( nano-chemotherapeutics ) have been widely employed for the treatment of solid tumours. The dimensions of nanoparticulate drug delivery systems also make them ideal vectors for improving drug exposure to the lymphatic system, potentially enhancing the treatment of lymph-resident metastases. This review examines the physical properties of nanoparticulate drug delivery systems that promote lymphatic exposure and lymph node retention, and discusses methods for improving lymphatic access. Drug delivery systems that have been investigated for the treatment of lymph node metastasis are also reviewed, and recent advances towards active targeting approaches for lymphatic metastases highlighted.
AB - Nano-sized drug delivery systems incorporating chemotherapeutic drugs ( nano-chemotherapeutics ) have been widely employed for the treatment of solid tumours. The dimensions of nanoparticulate drug delivery systems also make them ideal vectors for improving drug exposure to the lymphatic system, potentially enhancing the treatment of lymph-resident metastases. This review examines the physical properties of nanoparticulate drug delivery systems that promote lymphatic exposure and lymph node retention, and discusses methods for improving lymphatic access. Drug delivery systems that have been investigated for the treatment of lymph node metastasis are also reviewed, and recent advances towards active targeting approaches for lymphatic metastases highlighted.
U2 - 10.1016/j.jconrel.2014.04.051
DO - 10.1016/j.jconrel.2014.04.051
M3 - Article
SN - 0168-3659
VL - 193
SP - 241
EP - 256
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -
